Partnership Seeks to Address Gaps in Diagnosing Sepsis

Sepsis continues to be a serious threat to patients globally. Recent studies estimate that more than 30 million people are impacted worldwide every year and may be implicated in 6 million deaths,1 David Dolinger, VP Product Realisation at QuantuMDx Group Limited, told MD+DI. Infection and drug resistance contribute significantly to sepsis risks. In neonatal care alone, it is estimated that one million newborn deaths each year are associated with maternal infection, such as maternal sepsis,2 pointed out Dolinger. And three out of every ten deaths because of neonatal sepsis are thought to be caused by resistant pathogens,3 he added. Last year, QuantuMDx and Ontera Inc. began collaborating on a next-generation solution for blood stream infection and drug resistance detection. The solution will draw from QuantuMDx’s rapid cell/sample preparation technology, CAPTURE-XT, as well as Ontera’s nanopore biosensor, currently utilized in their SAM and DUO Nano platforms. “The combined technologies will be utilized to concentrate the causative etiological agent(s) and then to identify and provide an initial susceptibility/resistance profile for the causative agent(s),” he said. “The solution will not detect biomarkers but will specifically concentrate and detect the causative agent(s).” Dolinger said that the approach is “address...
Source: MDDI - Category: Medical Devices Authors: Tags: IVD Source Type: news